Kazia Therapeutics Limited (KZIA)
NASDAQ: KZIA · Real-Time Price · USD
7.18
+0.18 (2.57%)
At close: Nov 6, 2026, 4:00 PM EST
7.31
+0.13 (1.81%)
After-hours: Nov 6, 2026, 5:32 PM EST
Kazia Therapeutics Revenue
Kazia Therapeutics had revenue of 14.01M AUD in the half year ending December 31, 2025, with 280,273,160.00% growth. In the fiscal year ending June 30, 2025, Kazia Therapeutics had annual revenue of 1.83M, down -26.30%. That makes Kazia Therapeutics the 43,229th largest company in the world by revenue and 5,993rd in the United States.
Revenue (ttm)
1.83M AUD
Revenue Growth
-26.30%
P/S Ratio
77.69
Revenue / Employee
304,853 AUD
Employees
6
Market Cap
98.39M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 1.83M | -652.76K | -26.30% |
| Jun 30, 2024 | 2.48M | 2.48M | 248,088.20% |
| Jun 30, 2023 | 1.00K | -24.00K | -96.00% |
| Jun 30, 2022 | 25.00K | -15.16M | -99.84% |
| Jun 30, 2021 | 15.19M | 14.19M | 1,426.13% |
| Jun 30, 2020 | 995.00K | -470.00K | -32.08% |
| Jun 30, 2019 | 1.47M | -11.64M | -88.82% |
| Jun 30, 2018 | 13.11M | 4.30M | 48.75% |
| Jun 30, 2017 | 8.81M | 4.74M | 116.46% |
| Jun 30, 2016 | 4.07M | 1.23M | 43.24% |
| Jun 30, 2015 | 2.84M | 2.41M | 562.47% |
| Jun 30, 2014 | 429.00K | -1.30M | -75.20% |
| Jun 30, 2013 | 1.73M | -644.00K | -27.13% |
| Jun 30, 2012 | 2.37M | 52.00K | 2.24% |
| Jun 30, 2011 | 2.32M | -7.59M | -76.58% |
| Jun 30, 2010 | 9.92M | 7.41M | 295.97% |
| Jun 30, 2009 | 2.50M | -12.40M | -83.20% |
| Jun 30, 2008 | 14.91M | -5.10M | -25.49% |
| Jun 30, 2007 | 20.01M | 1.77M | 9.69% |
| Jun 30, 2006 | 18.24M | 560.00K | 3.17% |
| Jun 30, 2005 | 17.68M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
KZIA News
- 2 days ago - Kazia Therapeutics Recognized as "Drug Discovery Company of the Year" in 2026 BioTech Breakthrough Awards - PRNewsWire
- 5 days ago - Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium - PRNewsWire
- 8 days ago - Kazia Therapeutics initiated with a Buy at Needham - TheFly
- 9 days ago - Kazia Therapeutics to Participate in Fireside Chat at Guggenheim 3rd Annual Healthcare Innovation Conference - PRNewsWire
- 17 days ago - Kazia Therapeutics initiated with a Buy at Guggenheim - TheFly
- 18 days ago - Leerink bullish on Kazia Therapeutics, initiates with an Outperform - TheFly
- 18 days ago - Kazia Therapeutics initiated with an Outperform at Leerink - TheFly
- 19 days ago - Kazia Therapeutics management to meet with BTIG - TheFly